LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
LakeShore Biopharma (NASDAQ:LSB), a global biopharmaceutical company, has received a preliminary non-binding acquisition proposal from Oceanpine Capital. The proposed all-cash transaction offers $0.86 per ordinary share for shares not currently owned by Oceanpine Capital.
The offer represents a 10.3% premium to LSB's last closing price on August 15, 2025, and an 11.4% premium to the 15-day average closing price. Oceanpine Capital plans to finance the transaction through rollover equity and available cash, with no financing condition attached. The company has engaged White & Case LLP as its international legal advisor.
LakeShore's Board of Directors will review and evaluate the proposal to determine the best course of action for the company and its shareholders. No decisions have been made regarding the company's response to the proposal.
LakeShore Biopharma (NASDAQ:LSB), societ脿 biofarmaceutica globale, ha ricevuto una proposta preliminare non vincolante di acquisizione da Oceanpine Capital. L'operazione proposta in contanti offre $0,86 per azione ordinaria per le azioni non gi脿 detenute da Oceanpine Capital.
L'offerta corrisponde a un premio del 10,3% rispetto al prezzo di chiusura di LSB del 15 agosto 2025 e a un premio dell'11,4% rispetto alla media di chiusura a 15 giorni. Oceanpine Capital intende finanziare l'operazione tramite equity di rollover e disponibilit脿 liquide, senza alcuna condizione di finanziamento. La societ脿 ha nominato White & Case LLP come consulente legale internazionale.
Il Consiglio di Amministrazione di LakeShore esaminer脿 e valuter脿 la proposta per decidere la migliore linea d'azione per la societ脿 e i suoi azionisti. Non 猫 stata presa alcuna decisione in merito alla risposta alla proposta.
LakeShore Biopharma (NASDAQ:LSB), una compa帽铆a biofarmac茅utica global, ha recibido una propuesta preliminar no vinculante de adquisici贸n por parte de Oceanpine Capital. La transacci贸n propuesta en efectivo ofrece $0,86 por acci贸n ordinaria por las acciones que Oceanpine Capital no posee actualmente.
La oferta representa una prima del 10,3% sobre el 煤ltimo precio de cierre de LSB del 15 de agosto de 2025 y una prima del 11,4% sobre el precio medio de cierre de 15 d铆as. Oceanpine Capital planea financiar la operaci贸n con capital de rollover y efectivo disponible, sin condici贸n de financiaci贸n. La compa帽铆a contrat贸 a White & Case LLP como asesora legal internacional.
El Consejo de Administraci贸n de LakeShore revisar谩 y evaluar谩 la propuesta para determinar la mejor acci贸n para la compa帽铆a y sus accionistas. No se ha tomado ninguna decisi贸n sobre c贸mo responder a la propuesta.
LakeShore Biopharma (NASDAQ:LSB), 旮�搿滊矊 氚旍澊鞓れ牅鞎� 旮办梾鞚� Oceanpine Capital搿滊秬韯� 鞓堧箘鞝� 牍勱惮靻� 鞚胳垬 鞝滌晥鞚� 氚涭晿鞀惦媹雼�. 鞝滌晥霅� 鞝勳暋 順勱笀 瓯半灅電� Oceanpine Capital鞚� 順勳灛 氤挫湢頃橃 鞎婌潃 氤错喌欤检棎 雽�頃� 欤茧嫻 $0.86毳� 鞝滌嫓頃╇媹雼�.
鞚� 鞝滌晥鞚� 2025雲� 8鞗� 15鞚� 旮办 LSB鞚� 毵堨毵� 膦呹皜 雽�牍� 10.3% 頂勲Μ氙胳梽, 15鞚� 韽夑窢 膦呹皜 雽�牍� 11.4% 頂勲Μ氙胳梽鞚� 鞚橂頃╇媹雼�. Oceanpine Capital鞚� 搿れ槫氩� 歆�攵� 氚� 氤挫湢 順勱笀鞙茧 瓯半灅毳� 鞛愱笀 臁半嫭頃� 瓿勴殟鞚措┌, 鞛愱笀 臁半嫭 臁瓣贝鞚� 鞐嗢姷雼堧嫟. 須岇偓電� 甑牅 氩曤 鞛愲鞙茧 White & Case LLP毳� 靹犾瀯頄堨姷雼堧嫟.
LakeShore 鞚挫偓須岆姅 須岇偓鞕� 欤检＜霌れ棎瓴� 斓滌劆鞚� 氚╈晥鞚� 瓴办爼頃橁赴 鞙勴暣 鞝滌晥鞚� 瓴�韱犿晿瓿� 韽夑皜頃� 瓴冹瀰雼堧嫟. 鞝滌晥鞐� 雽�頃� 須岇嫚 鞐秬鞐� 甏�頃� 鞎勳 瓴办爼霅� 靷暛鞚� 鞐嗢姷雼堧嫟.
LakeShore Biopharma (NASDAQ:LSB), une entreprise biopharmaceutique mondiale, a re莽u une proposition pr茅liminaire d'acquisition non contraignante de Oceanpine Capital. La transaction propos茅e en num茅raire offre 0,86 $ par action ordinaire pour les actions que Oceanpine Capital ne d茅tient pas actuellement.
L'offre repr茅sente une prime de 10,3 % par rapport au dernier cours de cl么ture de LSB du 15 ao没t 2025 et une prime de 11,4 % par rapport 脿 la moyenne des cours de cl么ture sur 15 jours. Oceanpine Capital pr茅voit de financer la transaction par une r茅partition d'actions rollover et des liquidit茅s disponibles, sans condition de financement. La soci茅t茅 a retenu White & Case LLP comme conseil juridique international.
Le conseil d'administration de LakeShore examinera et 茅valuera la proposition afin de d茅terminer la meilleure marche 脿 suivre pour la soci茅t茅 et ses actionnaires. Aucune d茅cision n'a encore 茅t茅 prise quant 脿 la r茅ponse 脿 cette proposition.
LakeShore Biopharma (NASDAQ:LSB), ein globales biopharmazeutisches Unternehmen, hat ein vorl盲ufiges, unverbindliches 脺bernahmeangebot von Oceanpine Capital erhalten. Die vorgeschlagene Bartransaktion bietet $0,86 pro Stammaktie f眉r die von Oceanpine Capital derzeit nicht gehaltenen Aktien.
Das Angebot entspricht einer Pr盲mie von 10,3% gegen眉ber dem letzten Schlusskurs von LSB am 15. August 2025 und einer Pr盲mie von 11,4% gegen眉ber dem 15-Tage-Durchschnittskurs. Oceanpine Capital plant die Finanzierung der Transaktion durch Rollover-Eigenkapital und vorhandene liquide Mittel, ohne Finanzierungsbedingung. Das Unternehmen hat White & Case LLP als internationalen Rechtsberater engagiert.
Der Vorstand von LakeShore wird das Angebot pr眉fen und bewerten, um den besten Kurs f眉r das Unternehmen und seine Aktion盲re zu bestimmen. Es wurden noch keine Entscheidungen zur Reaktion auf das Angebot getroffen.
- Acquisition offer represents a 10.3% premium to last closing price
- No financing condition attached to the proposed transaction
- 11.4% premium to the 15-day average closing price
- Transaction to be funded with readily available cash and rollover equity
- Preliminary and non-binding nature of the proposal creates uncertainty
- No guarantee of deal completion or improved terms
- Potential loss of independent public company status if acquired
Insights
Oceanpine's $0.86/share offer for LakeShore Biopharma represents modest 10.3% premium; deal appears to be in early stages.
This preliminary acquisition proposal from Oceanpine Capital to acquire LakeShore Biopharma represents a relatively modest premium of
The
This proposal is still in the very preliminary stages. The Board has just received it and hasn't made any decisions. Several critical factors will influence their evaluation: the company's cash position, pipeline prospects, burn rate, and alternative strategic options. The lack of a financing condition is positive, suggesting Oceanpine has secured sufficient capital for the transaction.
The announcement's cautious language - emphasizing the non-binding nature and that no decisions have been made - suggests the Board may seek a higher offer or explore alternative transactions. Shareholders should recognize that this marks the beginning of what could be a lengthy negotiation process, with no guarantee of completion at the currently proposed price.
The proposed purchase price represents a premium of
The Board has just received the Proposal Letter and will carefully review and evaluate the proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders.
The Company cautions its shareholders and others considering trading in its securities that the Board has just received the Proposal Letter and has not made any decisions with respect to the Company's response to the proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed, or that the Proposed Transaction or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA庐 immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the Board's evaluation of the Proposal Letter and the Proposed Transaction. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "potential," "forecast," "intend," "will," "expect," "anticipate," "believe," "goal," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's management and are not predictions of actual performance.
LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the Company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.
Exhibit A
Preliminary Non-Binding Proposal
August 18, 2025
The Board of Directors (the "Board")
LakeShore Biopharma Co., Ltd
Building No. 2, 38 Yongda Road
Daxing Biomedical Industry Park
Daxing District,
Dear members of the Board:
We, Oceanpine Investment Fund II LP and Oceanpine Capital Inc. ( collectively, "Oceanpine Capital"), are pleased to submit this preliminary non-binding proposal (the "Proposal") to acquire all outstanding ordinary shares of a par value of
Our Proposal represents a premium of
We intend to fund the Proposed Transaction with rollover equity and available cash on hand. Accordingly, our Proposal would not be subject to any uncertainty or delay with respect to any debt financing, and the Proposed Transaction will not be subject to a financing condition.
We do not anticipate any substantive issues with respect to regulatory approvals, nor do we believe that any regulatory approval will impede or delay our ability to quickly and efficiently consummate the Proposed Transaction.
We have engaged White & Case LLP as our international legal advisor for the Proposed Transaction. We are confident that we can complete customary due diligence in a timely manner, in parallel with discussions on the definitive agreements.
We recognize that the Board will likely need to evaluate our Proposal independently before the Company can make any determinations. None of the Company's directors who are affiliated with us will participate in the consideration of our Proposal by the Company.
While we are fully prepared to work collaboratively with the Board to pursue the Proposed Transaction in a timely manner, we are open to exploring potential alternative structures of the Proposed Transaction to expedite the process of delivering value to the Company's shareholders.
Following completion of the Proposed Transaction, we currently intend for the Company's business to continue operating in a manner that is generally consistent with its current operations.
This letter constitutes only a preliminary indication of our interest and does not constitute any binding commitment with respect to the transactions proposed in this letter or any other transaction. No agreement, arrangement or understanding between us and the Company relating to any transaction will be created until such time as definitive documentation has been executed and delivered by us and the Company and all other appropriate parties.
About Oceanpine Capital
Founded in 2018, Oceanpine Capital is a professional investment management firm dedicated to long-term value investing. With a mission to drive technological innovation, it focuses on cutting-edge sectors such as advanced technology, green technology and life sciences, with assets under management exceeding
Should you have any questions regarding this Proposal, please do not hesitate to contact us. We look forward to hearing from you.
Sincerely,
Oceanpine Investment Fund II LP
By: | /s/ Dave Liguang Chenn |
Name: | Dave Liguang Chenn |
Title: | Director |
Oceanpine Capital Inc.
By: | /s/ Yang Jiayu |
Name: | Yang Jiayu |
Title: | Director |
听
View original content:
SOURCE LakeShore Biopharma Co., Ltd.
FAQ
What is the offer price for LakeShore Biopharma (LSB) shares in the acquisition proposal?
What premium does the LSB acquisition offer represent to shareholders?
How will Oceanpine Capital fund the acquisition of LakeShore Biopharma?
What is the current status of the LSB acquisition proposal?
Who is the legal advisor for the LSB acquisition?
